OTCMKTS:DSRLF - DiaSorin Stock Price, Price Target & More

$90.2632 +1.00 (+1.13 %)
(As of 04/20/2018 04:00 PM ET)
Previous Close$89.2590
Today's Range$90.2632 - $90.2632
52-Week Range$84.7464 - $98.6933
Volume100 shs
Average Volume1,543 shs
Market Capitalization$5.05 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About DiaSorin (OTCMKTS:DSRLF)

DiaSorin S.p.A. engages in the development, production, and commercialization of diagnostic tests that are designed for hospital and private testing laboratories for use in various clinical areas in the market of immunodiagnostics and molecular diagnostics. The company offers immunodiagnostics products in the areas of infectious diseases; bone and mineral metabolism; endocrinology, including diabetes, thyroid function, fertility, growth, adrenal function, and gastroenterology; hypertension; oncology; stool diagnostics; autoimmunity; and cardiac and brain damages. Its immunodiagnostics systems include LIAISON XL, an automated chemiluminescence analyzer; LIAISON analyzer; EVOlyzer 2-150/8 with disposable tips; and ETI Max 3000, an automated microtiter plate analyzer. The company also offers molecular diagnostic products for oncology, hematology, and infectious diseases; systems, including BULLET Pro and LIAISON Ixt to extract the nucleic acid from various biological samples; and LIAISON Iam to diagnose and various infectious diseases and onco-hematology parameters. It sells its products directly, as well as through an international network of independent distributors in Europe, Africa, Central America, South America, the Asia Pacific, and North America. DiaSorin S.p.A. was founded in 1968 and is headquartered in Saluggia, Italy.

Receive DSRLF News and Ratings via Email

Sign-up to receive the latest news and ratings for DSRLF and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Private households
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:DSRLF
CUSIPN/A
Phone390-161-4871

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E Ratio25.57
P/E Growth2.77

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding Shares55,950,000

How to Become a New Pot Stock Millionaire

DiaSorin (OTCMKTS:DSRLF) Frequently Asked Questions

What is DiaSorin's stock symbol?

DiaSorin trades on the OTCMKTS under the ticker symbol "DSRLF."

Who are some of DiaSorin's key competitors?

Who are DiaSorin's key executives?

DiaSorin's management team includes the folowing people:
  • Mr. Carlo Rosa, CEO, GM & Exec. Director (Age 52)
  • Dr. Chen Menachem Even, Chief Commercial Officer & Exec. Director (Age 55)
  • Mr. Piergiorgio Pedron, Corp. Accounting Documents Officer, CFO & Sr. Corp. VP (Age 47)
  • Mr. Riccardo Fava, Sr. Director of Investor Relations & Corp. Communication
  • Mr. Marco Minolfo, Mang. of the Corp. Legal Affairs Department

Has DiaSorin been receiving favorable news coverage?

News stories about DSRLF stock have been trending somewhat positive on Saturday, according to Accern Sentiment Analysis. The research group identifies negative and positive media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. DiaSorin earned a daily sentiment score of 0.10 on Accern's scale. They also gave news stories about the company an impact score of 45.31 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

How do I buy shares of DiaSorin?

Shares of DSRLF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is DiaSorin's stock price today?

One share of DSRLF stock can currently be purchased for approximately $90.2632.

How big of a company is DiaSorin?

DiaSorin has a market capitalization of $5.05 billion.

How can I contact DiaSorin?

DiaSorin's mailing address is Via Crescentino, Saluggia L6, 13040. The company can be reached via phone at 390-161-4871 or via email at [email protected]


MarketBeat Community Rating for DiaSorin (DSRLF)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  14 (Vote Outperform)
Underperform Votes:  13 (Vote Underperform)
Total Votes:  27
MarketBeat's community ratings are surveys of what our community members think about DiaSorin and other stocks. Vote "Outperform" if you believe DSRLF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DSRLF will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

DiaSorin (OTCMKTS:DSRLF) Analyst Ratings History

DateBrokerageActionRatingPrice TargetDetails
(Data available from 4/21/2016 forward)

Earnings

Dividends

DiaSorin (OTCMKTS:DSRLF) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

DiaSorin (OTCMKTS DSRLF) Insider Trading and Institutional Ownership History

Insider Trading History for DiaSorin (OTCMKTS:DSRLF)

DiaSorin (OTCMKTS DSRLF) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

DiaSorin (OTCMKTS DSRLF) News Headlines

Source:

SEC Filings

DiaSorin (OTCMKTS:DSRLF) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

DiaSorin (OTCMKTS DSRLF) Stock Chart for Saturday, April, 21, 2018

Loading chart…

This page was last updated on 4/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.